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Abstract
Cancer is a leading cause of death worldwide, and its incidence is increasing due to modern
lifestyle that prolonged human life. All cancers originate from a single cell that had acquired
genetic aberrations enabling uncontrolled proliferation. Each cancer is unique in its aberrant
genetic makeup, which defines, to large extent, its biology, aggressiveness, and vulnerabilities
to different treatments. Furthermore, the genetic makeup of each cancer is heterogeneous
among its constituent cancer cells, and dynamic with the ability to evolve in order to preserve
the survival of cancer cells. Sequencing technologies are currently producing massive
amounts of data that, with the help of specialized computational methods, can revolutionize
our knowledge on cancer.
A key question in cancer research is how to personalize the treatment of cancer patients, so
that each cancer is treated according to its molecular characteristics. The first study in this
thesis takes a step in that direction through a proposed novel molecular classification system
of diffuse large B-cell lymphoma (DLBCL), which is the most common hematological
malignancy in adults. The suggested classification, derived from the integrative analysis of
gene expression and DNA mutations, stratifies DLBCL into four groups with distinct biology,
genetic landscapes, and clinical outcome. These subtypes could help identify patients at high
risk who may benefit from an altered treatment plan.
Understanding the genomic evolution of cancer that transforms a typically curable primary
tumor into an incurable drug-resistant metastasis is another aspect of cancer research under
intensive investigation. The second study in this thesis investigates the spreading patterns of
metastasis in breast cancer, which is the most common cancer in women. Using phylogenetic
analysis of somatic mutations from longitudinal breast cancer samples, the metastasis routes
were uncovered. The study revealed that breast cancer spreads either in parallel from primary
tumor to multiple distant sites, or linearly from primary tumor to a distant site, and then from
that to another. However, in all cases, axillary lymph nodes did not mediate the spreading
to distant sites. This provided a genetic-based evidence on the redundancy of lymph node
dissection in breast cancer management.
Towards a genetic-based diagnostics in cancer, the computational methods used to detect
genetic aberrations need to be evaluated for their accuracy. The third study in this thesis
performs a comparison of methods for detecting somatic copy number alterations from
cancer samples. The study evaluated several commonly used methods for two different
sequencing platforms using simulated and real cancer data. The results provided an overview
of the weaknesses of the different methods that could be methodologically improved.
Altogether, this thesis gives an overview on the field of computational cancer genomics and
presents three studies that exemplify the clinical relevance of computational research.
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1. INTRODUCTION
1 Introduction
Cancer incidence was estimated at 18 million new cases worldwide in 2018, and is
projected to increase to 29.5 million in 2040 [1, 2]. Cancer is the second leading
cause of death, and was responsible for about 9.6 million deaths worldwide in
2018 [1, 2]. Due to its increasing social and economic impact, cancer research has
been continuously growing through the years, aiming at understanding cancer and
exploring new effective treatment strategies.
Cancer is a genetic disease. Although the implication of the genome in cancer
development was discovered in the late 19th and early 20th centuries [3, 4], it
was not until 1982 when the first DNA point mutation in cancer genome was
discovered [5]. This discovery marked the beginning of a quest for finding cancer
genes. The completion of the first draft of the human genome sequence in 2001 [6],
and the launch of The Cancer Genome Atlas (TCGA) project [7] were two major
milestones in the high-throughput cancer genomics field. The TCGA project aimed
at generating comprehensive maps of the genomic changes in 33 types of cancer
producing data from more than 10,000 cancer patients.
Since the completion of the human genome, the costs of sequencing have been
continuously decreasing, and the amounts of generated sequence data are rapidly
growing. The storage, analysis and interpretation of the vast amounts of gen-
erated data became the new bottleneck in modern genome research [8]. With
these challenges, the role of bioinformatics became increasingly important as a
multidisciplinary field that uses computational and statistical approaches to derive
insights from biological data. This thesis covers a background in cancer genomics
and the computational approaches used in analyzing cancer genome data, and
discusses three studies on computational cancer genomics.
The first study in this thesis used computational methods to classify diffuse large
B-cell lymphoma (DLBCL) into four subtypes with distinct clinical outcome.
DLBCL is an aggressive and the most common type of non-Hodgkin lymphoma
(NHL). NHL incidence was estimated at about 509,000 cases, and accounted for
248,000 cancer-related deaths globally in 2018 [2]. DLBCL is curable in 60% of
all cases [9, 10], and therefore stratifying DLBCL patients into groups with unique
clinical outcomes is crucially important.
The second study investigated the genomic evolutionary path of breast cancer
metastasis. Breast cancer is the most common malignancy in women accounting
for more than two million new cases and 626,000 deaths worldwide in 2018 [2].
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Metastatic breast cancer remains incurable, and is almost exclusively responsible for
mortality in breast cancer patients [11]. Therefore, understanding the evolutionary
origin of breast cancer metastasis is of high importance.
DNA sequencing experiments can inform on all kinds of genetic alterations in the
genome, and genetic testing is increasingly becoming clinically relevant. However,
in order for the derived information to be meaningful, the employed computational
tools need to be accurate. The third study compared the performance of several
computational methods for detecting somatic copy number alterations (SCNAs)
from DNA sequencing data. SCNAs constitute an important class of genetic
alterations affecting the dosage of up to thousands of genes simultaneously, and
their accurate detection is a major step in analyzing cancer genomes.
Both Publication I and Publication II in this thesis investigate highly heterogeneous
cancers. Both DLBCL and breast cancer are divided into different subtypes with
significantly different outcome. The first study takes the approach of discerning
unexplained heterogeneity in the primary tumor in order to enhance the therapeutic
choices of the patients at risk, and thereby reducing recurrence rate. The second
study aims at understanding the genomic evolution of recurrence (in the form of
metastasis) in order to inform the therapeutic choices after metastasis. The analysis
of genomic evolution in Publication II depends on the detected SCNAs, which are
heavily studied in Publication III.
The thesis proceeds with a review of the literature on cancer genomics with
particular focus on lymphoma and breast cancer. Additionally, some of the main
computational approaches used in investigating cancer genomes are discussed and
reviewed.
2
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2 Review of the literature
2.1 Biology of cancer
2.1.1 Cancer hallmarks
Cancer encompasses a group of diseases characterized by uncontrolled proliferation
of cells that can cross the normal tissue boundaries and metastasize to distant
sites [12]. Human cancer cells can originate from most cell types in human
body, and the cell of origin constitutes the main way of cancer classification.
Malignant transformation of normal cells occurs by acquiring special capabilities
that give selective advantage to cancer cells over non-cancerous ones. These special
capabilities are called the hallmarks of cancer [13, 14]. Although all types of cancer
share the same hallmarks, the mechanisms through which individual cancers acquire
those hallmarks are highly heterogeneous [13, 14]. Furthermore, the chronological
order of acquiring cancer hallmarks also varies among cancers [13, 14]. Figure 1
shows a list of cancer hallmarks observed in different cancers.
2.1.2 Cancer initiation
All cancers develop as a result of genetic alterations in the genomes of cancer
cells [12]. Cancer capabilities of growth and invasion are acquired through a
multi-step process that resembles Darwinian evolution among cell populations
[15, 16]. Normal cells continuously acquire somatic mutations during mitotic
cell divisions due to exogenous or endogenous exposure to various mutagens or
mutational processes [17, 18]. The random acquisition of mutations is followed
by selection. Cells carrying mutations that confer a survival and proliferation
advantage are selected over their neighbour cells [19]. Cancer initiates as a result of
clonal expansion of a single cell that have acquired a set of advantageous mutations
sufficient for malignant transformation [12]. These mutations are called driver
mutations.
The number of driver mutations required for malignant transformation varies among
different cancers, and was estimated to be fewer than ten mutations for the majority
of cancers (considering only base substitutions) [20]. Given the nature of ongoing
mutagenesis in normal cells, the likelihood of reaching malignant transformation
increases with age, which is the most prominent risk factor [21]. However, there are
other factors that increase cancer risk. Environmental exposure to mutagens such
3
2. REVIEW OF THE LITERATURE
Figure 1: The ten hallmarks of cancer. Edited from [14] with permission from Elsevier
Inc.
as tobacco smoking and UV light increases the rate of mutagenesis in the exposed
tissue contributing to higher cancer risk. Viral infection inserts completely new
DNA sequences in the genome and contribute to the genesis of several cancer types
[22]. Hereditary factors explain cancer incidence in a sizable fraction of cancers
[23]. Inherited deleterious germline mutations can be drivers of cancer making
their harboring cells one step ahead towards malignant transformation, or they can
disrupt the DNA repair machinery accelerating endogenous mutagenesis.
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Figure 2: Illustration of several modes of evolution in cancer. Edited from [27] with
permission from Elsevier Inc.
2.1.3 Intratumor heterogeneity and clonal evolution
Cancer cells continue to evolve after clonal expansion of the malignant progenitor
cell by the same mechanism: mutagenesis and selection. However, evolution of
malignant cells is further fueled by their genomic instability and by activating
additional mutational processes that accelerate acquisition of mutations [24, 25].
The ongoing evolution contributes to the genetic and phenotypic diversification of
cancer cells within the same tumor. The phenomenon of diversified cancer cells
is called intratumor heterogeneity (ITH). Although genomic alterations are the
major source of ITH, epigenetic mechanisms including DNA methylation, histone
modifications and chromatin remodeling also contribute to ITH [26].
ITH manifests as spatial heterogeneity between genetically distinct cell populations,
or temporal heterogeneity reflecting dynamic clonal composition over time. Tempo-
ral evolution is particularly apparent under selective pressure imposed, for example,
by treatment [24]. Genetically distinct cancer cell populations can have differential
response to treatment, and therefore, their survival and selective advantage may
change after the treatment bottleneck. Changing microenvironment is another
5
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bottleneck that shakes the fitness of different cancer cell populations. For example,
the growth advantage of different cancer cell populations can change after metastasis
to distant sites with different microenvironment [28].
Several patterns of evolution govern the dynamics of clonal diversification in cancer
(Figure 2) [29]. In linear evolution, subclones arise sequentially in a step-wise
manner corresponding to higher clonal fitness at each step that may or may not
lead to full clonal sweep of previous cell populations [30, 29]. Branching evolution
describes the case when two or more subclones diverge from a common ancestor
and continue to expand and co-exist in the tumor [29]. Neutral evolution assumes
that there is no selection during most of the lifetime of the tumor leading to neutral
growth of clones rather than clonal expansion [29, 27]. The patterns of evolution
vary among individual cancers, and may operate simultaneously or at different
stages of cancer progression within the same tumor [29, 27].
2.1.4 Inter-individual variability and precision medicine
The nature of cancer evolution leads to pronounced diversity among individual
cancers such that each individual tumor is genetically unique. The genetic diversity
reflects into unique aggressiveness and response to different treatments for each
cancer. Precision medicine attempts to match the right treatment to the right
patient based on the unique characteristics of each tumor [31]. The identification of
prognostic and predictive biomarkers promotes personalized treatment of cancer.
Prognostic biomarkers inform on the aggressiveness of the disease and evaluate the
overall patient outcome after standard treatment, whereas predictive biomarkers
predict the response to a specific cancer treatment [32]. Molecular classification of
cancer divides a certain type of cancer into biologically distinct subgroups that may
have unique prognosis and response to treatment [33, 34].
2.1.5 Metastasis
The vast majority of cancer-related deaths is due to metastasis [35]. Metastasis
occurs as a multi-stage process that sequentially involves local invasion, intrava-
sation, survival in the circulation, arrest at a distant organ site, extravasation,
micrometastasis formation and metastatic colonization [36]. The genetic makeup
of metastasis differs from that of its respective primary tumor, which further
complicates the treatment of metastatic cancers. Metastatic dissemination can be
described by two models: the linear progression model and the parallel progression
6
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Figure 3: Illustration of the linear progression model (a) and parallel progression model
(b) of breast cancer metastasis, together with corresponding possible phylogenetic trees.
Edited from [39] with permission from Springer Nature.
model [37, 38]. The linear progression model assumes that metastatic dissemination
occurs late in tumorigenesis leading to a small degree of genetic divergence between
metastasis and its respective primary tumor [37, 38]. In parallel progression,
the metastatic clone leaves the primary tumor early and continues to evolve
independently in parallel with the primary tumor leading to a substantial genetic
divergence [37, 38].
7
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Metastatic spreading to multiple different distant sites could also be described by
linear or parallel spreading patterns [37, 39]. In linear spreading, metastases spread
from one site to another sequentially accumulating further genetic alterations at each
step. Alternatively, metastatic clones can spread directly from the primary tumor
to different metastasis sites, and each evolves independently in parallel (Figure
3). Metastatic seeding could be polyclonal in which more than one clone seed the
metastasis, in contrast to monoclonal seeding, where seeding occurs by only one
clone [37]. The patterns of metastatic progression, spreading and seeding varies
among different cancers and even within individual cancers [37].
2.2 Cancer genomics
2.2.1 Genetic alterations in cancer
Unlike inherited germline variations, somatic mutations arise in somatic cells and
pass to the progeny of a mutated cell by mitotic cell divisions [12]. Somatic
mutations include all kinds of genetic alterations in the DNA sequence ranging in
size from a single nucleotide to a whole chromosome or even the whole genome [40].
Single nucleotide substitutions or point mutations change a single nucleotide to
another, and can be either transitions (purine to purine or pyrimidine to pyrimidine)
or transversions (purine to pyrimidine or vice versa). Small insertions or deletions
(indels) affect few bases of DNA sequence. Somatic copy number alterations
(SCNAs) include amplifications or deletions of a chromosomal segment that range
in size from small focal alterations to arm-level chromosomal events. Structural
variations (SVs) include insertions, deletions, inversions, tandem duplications,
intra- and inter-chromosomal translocations. SVs may or may not be balanced
in preserving the copy number after alterations. Similarly, loss of heterozygosity
(LOH) may or may not change the copy number while leading to allelic loss of
a genomic segment. Whole-genome doubling is a single event that leads to the
duplication of a complete set of chromosomes [41]. Figure 4 shows several types
of genetic alterations and their manifestation in sequencing reads.
Genetic alterations can have various effects depending on their type, size and
location. Point mutations and indels in the exons of protein-coding genes may
alter the amino acid sequence of a protein or lead to an immature stop codon [40].
These changes can cause a gain or loss of function for the disrupted protein. Small
alterations in the non-coding regions of intragenic or intergenic regions may alter
the splicing of a gene or disrupt DNA elements such as promoters and enhancers.
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Figure 4: Illustration of the manifestation of several types of genetic alterations in
sequencing reads. Edited from [42] with permission from Springer Nature.
SCNAs lead to changes in expression of their target genes that range from one in
focal alterations to thousands in chromosomal alterations [43]. SVs can juxtapose
parts of two genes, leading to gene fusion products with altered oncogenic functions.
From evolutionary perspective, accumulation of genetic alterations occurs grad-
ually or as bursts of punctuated evolution [29]. In punctuated evolution, several
alterations arise in one single event. SCNAs have been shown to follow punctuated
evolution in triple-negative breast cancer [44]. Other punctuated evolution events
include chromothripsis (from Greek for chromosome shattering), chromoplexy and
kataegis (from Greek for thunderstorm). Chromothripsis is a single catastrophic
event by which up to thousands of localized chromosomal rearrangements occur
simultaneously [45]. Chromoplexy is a series of complex rearrangements occurring
as closed chains without genomic loss [46]. Kataegis is a phenomenon of localized
cytosine-to-thymine hypermutation attributed to activity of the APOBEC family of
cytidine deaminases [47].
9
2. REVIEW OF THE LITERATURE
2.2.2 Etiology of genetic alterations
Genetic alterations are caused by various exogenous and endogenous factors.
Exposure to environmental mutagens such as radiation, tobacco smoking, and
ultraviolet (UV) light can cause DNA damage, and ultimately leads to mutations.
Mutagenesis can also arise due to endogenous factors. DNA is replicated during
each cell division by DNA polymerases. Replication is estimated to generate
a constant rate of mutations, especially through increased transient exposure of
single-strand DNA to spontaneous deamination of methylated cytosines that can
ultimately lead to C>T substitutions at CpG context [48]. C>T transitions in
CpG sites constitute the most prevalent mutational pattern in cancer, and their rate
significantly correlate with age in many cancer types [49]. Single-strand DNA is
also a substrate for enzymatic editing by the family of cytidine deaminases such as
APOBEC enzymes that constitute the second most prevalent source of mutations
in cancer [48, 49]. The increased transient exposure of single-strand DNA to
mutagenesis is also apparent during transcription within the transcription bubble
formed by RNA polymerase [50]. Transcription-coupled mutagenesis typically
exhibit transcriptional strand asymmetry since the DNA repair machinery is more
likely to be invoked by a damage that stalls the RNA polymerase on the transcribed
strand [51].
DNA is continuously exposed to endogenous DNA damage sources such as hydrol-
ysis and oxidation [52]. DNA damage can also occur due to an oncogene-induced
replication stress that ultimately leads to double-strand breaks (DSBs), the most
dangerous form of DNA damage [53]. DSBs and chromosomal instability have
been also attributed to other mechanisms such as telomere attrition and centrosome
abnormalities [54, 55]. It has been estimated that each human cell encounters
approximately 70,000 lesions per day [48]. Luckily, the vast majority of the
encountered damage is counteracted by effective DNA repair mechanisms, or other
protective mechanisms that lead to cell-cycle arrest or apoptosis [56].
Different kinds of DNA damage are repaired by distinct repair mechanisms. Defects
in DNA repair mechanisms through inherited germline or somatic mutations can
lead to increased mutational load, cancer and other diseases. The type of genetic
alterations induced by DNA repair deficiencies depends on the defective mechanism
and the type of defect. For example, defective homologous recombination (HR)
repair leads to a distinct signature of mutations and structural variations depending
on the type of defect in the pathway [57]. Other unique mutational signatures have
been attributed to deficiencies in mismatch repair and nucleotide excision repair
10
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pathways [58].
Repair of DNA damage can be error-prone introducing genetic alterations. For
example, DSBs can be repaired by either the high-fidelity homologous recom-
bination (HR) pathway or the error-prone non-homolougous end joining that
leaves rearrangements in the genome [59]. DNA polymerases are involved in
DNA repair and recruited by different pathways [60]. The fidelity of repair also
varies depending on the recruited polymerase. Error-prone polymerases allow the
completion of replication and avoidance of replication fork collapse at the cost of
introducing errors [58, 60]. The genetic alterations left in the genome by error-prone
mechanisms typically have distinct signatures. For example, processing with the
non-canonical non-homolougous end joining leaves rearrangements with microho-
mology at breakpoint junctions, and recruitment of the error-prone polymerase η
leads to thymine mutations at TW context (W is A or T) [58, 59].
2.2.3 Cancer genes
Cancer genes are those causally implicated in cancer development [61]. Driver
mutations in cancer genes confer a selective advantage to the tumor. Therefore,
the number or pattern of mutations in a gene that cannot be expected by chance
is indicative of positive selection and a driver role of that gene [61]. Driver genes
are distinguished from other passengers whose mutations do not promote growth
advantage of cancer cells. Driver genes have been identified based on the frequency
[62, 63], the positional clustering [64], and the predicted deleterious function [65]
of their mutations. However, not all mutations in driver genes are driver mutations.
In fact, identification of driver mutations is more challenging than finding driver
genes [40]. Although protein coding genes constitute a very small fraction of the
genome, the identified driver mutations in the non-coding genome are so far not
common [66]. However, there are established examples where the non-coding
genome is implicated in tumorigenesis such as TERT promoter mutations [67],
translocations involving the immunoglobulin locus in B-cell lymphomas [68], and
oncogene activation by enhancer hijacking [69].
Cancer genes can be classified into oncogenes or tumor suppressor genes (TSGs)
[40]. Activation of oncogenes via activating mutations, copy number amplifications
or gene-fusions promotes cancer growth. In contrast, loss-of-function mutations,
deletions or promoter hypermethylation inactivate TSGs and promote cancer.
Unlike oncogenes, TSGs were thought to be recessive; that is biallelic inactivation
is needed to promote cancer [70]. This two-hit model of tumorigenesis have been
11
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reevaluated after observations of haploinsufficient and gain of function phenotypes
of TSGs [71]. TSGs can be categorized into gatekeepers or caretakers. Gatekeepers
directly inhibit tumor growth or promote tumor death, and their inactivation directly
contributes to cancer initiation or progression [72]. In contrast, inactivation
of caretakers leads to increased accumulation of genomic alterations indirectly
promoting cancer development [72].
2.3 Lymphoma
Lymphoma encompasses a group of malignancies that arise from lymphocytes
that are at various stages of development. Lymphomas are traditionally divided
into Hodgkin’s lymphoma and non-Hodgkin lymphoma (NHL). NHL accounts
for about 90% of all lymphomas [73], and more likely affects B-cells than T-cells
or natural killer cells, owing to the unique biology of B-cells. In this section, I
review non-Hodgkin B-cell lymphomas with particular focus on diffuse large B-cell
lymphoma (DLBCL), the most common type of NHL.
2.3.1 B-cell development and lymphomagenesis
B lymphocytes in mammals develop from hematopoietic precursor cells in the
bone marrow [74]. Rearrangements of the immunoglobulin heavy chain and the
immunoglobulin light chain gene segments occur in the bone marrow generating a
B-cell repertoire capable of recognizing more than 5×1013 different antigens [74].
Immature B-cells that have survived positive selection for affinity and negative
selection for autoreactivity leave the bone marrow and migrate to the spleen, where
they differentiate into naive, follicular or marginal zone B cells [74]. Activation
of B-cells occurs in the secondary lymphoid organs after antigen encounters, with
or without the help of T-cells. Germinal centers are transient structures of fast
proliferating B-cells that form within secondary lymphoid organs during T-cell
dependent activation [75]. A process termed affinity maturation takes place in the
germinal center [76]. Affinity maturation is a result of iterative rounds of somatic
hypermutation (SHM) and affinity-based selection [76]. SHM randomly introduces
nucleotide substitutions in the variable region of immunoglobulin genes, which
acts as a fine-tuning step of the already rearranged immunoglobulin to enhance
antigen affinity [76]. Class switching also occurs in the germinal center by a process
called class switch recombination, where antibodies of classes M and D switch to
classes G, A or E [77]. Ultimately, B-cells in the germinal center become long-lived
12
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Figure 5: The cell of origin for various B-cell neoplasms. Edited from [78] with
permission from Annual Reviews, Inc.
memory B-cells or plasma cells residing in secondary lymphoid organs or in the
bone marrow [74].
Lymphomagenesis can occur at various stages of B-cell differentiation resulting
in different types of lymphomas with distinct pathological and clinical features
(Figure 5) [78, 79]. Malignant B-cells bear a phenotypic resemblance in gene
expression and immunoglobulin hypermutation to normal B-cells at a certain stage
of differentiation [78]. This resemblance constitutes the basis for determining the
cell of origin (COO) for different B-cell malignancies, and for subtype classification
13
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of histologically indistinguishable lymphomas [78]. For example, most mantle cell
lymphomas show resemblance in gene expression profile to pre-germinal center
B-cells, whereas most follicular lymphomas are similar to germinal center B-cells.
About 95% of lymphomas originate from B-cells despite the similar frequency of
B and T cells in the human body [80]. This is because the same mechanisms used
by B-cells for antibody diversity likely underlie lymphomagenesis. The frequent
chromosomal translocations in B-cell lymphomas are thought to be mediated
by aberrant rearrangements of the immunoglobulin gene, SHM or class switch
recombination [81]. Aberrant SHM is also responsible for oncogene activation by
off-targeting non-immunoglobulin genes [82].
2.3.2 Somatic hypermutation
Somatic hypermutation (SHM) mediates affinity maturation by introducing point
mutations into the variable region of the immunoglobulin genes in germinal center
B-cells. SHM mutations have several properties: (1) they accumulate up to 1.5 - 2.0
kbp downstream of transcription start sites [83], (2) they require and correlate with
transcription although transcription alone is not sufficient for SHM [84, 85], and
(3) they are preferentially targeted to to cytosines within WRCH motif or thymines
within the TW motif (W is A or T; R is A or G; H is A, C, or T) [86].
SHM is initiated by the activation-induced cytidine deaminase (AID), which
deaminates cytosines creating uracil mismatches. Three possible pathways can
repair the uracil mismatch: (1) proceeding with replication that produces C >
T transitions, (2) removal of uracils resulting in abasic sites, that either lead
after replication to any of the four bases, or proceed with further processing by
error-prone polymerases such as polymerase η , and (3) recognition by MSH2 and
MSH6 mismatch repair enzymes and further processing by error-prone polymerases
(Figure 6) [87, 88, 89]. Recruitment of error-prone polymerases may also introduce
additional mutations in the vicinity of the site of deamination.
SHM mistargeting was seen in several B-cell lymphomas leading to mutations
downstream of transcription start sites of several proto-oncogenes [82, 90, 91].
Off-target mutations by SHM are not random, but rather occur recurrently in
specific regions in the genome [90]. The specificity of AID targeting is still
not well understood. However, several features significantly associate with AID
targets. Transcription levels are significantly higher in AID target genes than
non-target genes [92]. The binding of RNAPolII and the stalling factor Spt5 is
higher within AID mutational targets [93, 92]. Finally, AID mutations associate
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Figure 6: Three possible pathways for the repair of uracil mismatches upon
AID-mediated deamination. Reprinted from [89] with permission from Springer
Nature.
with genomic regions of active enhancers and transcriptional elongation, the vicinity
of superenhancers and regions of convergent transcription [92, 94, 95].
2.3.3 Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL
accounting for 30 – 40% of all new NHL cases. Although DLBCL is an aggressive
lymphoma, the current standard immunochemotherapy regimen consisting of the
CD20 antibody rituximab in addition to cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP) cures approximately 60% of patients [9, 10]. Patients
who fail R-CHOP treatment present with a refractory or relapsed disease with
dismal outcome [96]. The International Prognostic Index (IPI) is a clinical tool
developed to predict the outcome in patients with DLBCL [97]. The IPI is based on
five criteria that associate with poor prognosis: (1) age >60, (2) stage III/IV, (3)
elevated serum lactate dehydrogenase level, (4) the patient performance status ≥2,
and (5) more than one extranodal disease sites [97].
DLBCL is classified using gene expression profiling into germinal center B-cell-like
(GCB), activated B-cell-like (ABC) and a third minor subtype that includes un-
classified cases [98]. GCB DLBCLs are believed, based on similarity in gene
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expression profile, to originate from normal B-cells in the germinal center, whereas
ABC DLBCLs are thought to originate from activated plasmablasts. This cell of
origin (COO) classification is associated with survival after standard treatment,
where ABC cases have significantly worse outcome [99, 100].
DLBCL is a genetically heterogeneous disease with a multitude of low frequency
driver alterations [101, 102, 103, 104]. Several of the recurrent driver alterations
are preferentially specific to either the GCB or ABC subtype, and some are
associated with survival [105]. Translocations of BCL2 and mutations in the
chromatin remodeling pathway are characteristic of a fraction of the GCB subtype
[79]. Constitutive NF-κB signaling and chronic active B-cell receptor signaling
are hallmarks of a fraction of ABC DLBCLs [79]. Co-occurrence of genomic
alterations in DLBCL was exploited to identify genetic subtypes with distinct
oncogenic signaling and clinical outcome [106, 107].
Most relapse cases of DLBCL occur within the first three years following treatment
[108]. The genetic landscape of relapsed DLBCL shows considerable differences
to that of the primary tumor [109]. Clonal evolution of DLBCL relapse was shown
to follow either late or early branching patterns reflecting various genetic similarity
to the primary tumor [110, 111]. The outcome of patients with relapsed DLBCL
is typically very poor, especially for those with early relapse [112]. Treatment of
relapsed or refractory DLBCL may involve high-dose therapy and autologous stem
cell transplantation, depending on patient age and performance status [96]. Patients
who cannot tolerate autologous stem cell transplantation are usually treated for
palliative purposes [96].
2.4 Breast cancer
Breast cancer is the most common malignancy and the first leading cause of
cancer death in women worldwide [2]. Breast cancer is clinically heterogeneous,
where early stage tumors are highly curable as opposed to metastatic cancers that
remain incurable [113]. Clinical and pathological variables are highly informative
for patient prognosis and treatment strategy selection. Lymph node metastasis,
tumor size, grade, and proliferation rate are all established prognostic markers [11].
The estrogen receptor (ER) status, progesterone receptor (PR) status, and human
epidermal growth factor receptor 2 (HER2) status are three essential biomarkers
that guide treatment strategies in breast cancer [114].
Treatment of breast cancer involves one or more of the following strategies [113].
Surgical removal of the tumor by entire breast removal (mastectomy) or by a
16
2. REVIEW OF THE LITERATURE
breast-conserving surgery (lumpectomy). Axillary lymph node dissection can
be a part of the main surgery or as a separate operation. Radiation therapy may
follow surgery in some cases of breast cancer. Hormone therapy can be used in
cancers with positive hormone receptors. Chemotherapy is the main treatment
for hormone receptor-negative cancers, and can be administered after surgery
(adjuvant), before surgery (neoadjuvant) or both. HER2-positive cancers can be
treated with trastuzumab, a targeted therapy that inhibits the HER2 protein [115]. A
fraction of breast cancers with BRCAness phenotype are eligible for treatment with
PARP inhibitors [116]. Despite of the plethora of clinical prognostic and predictive
biomarkers in breast cancer, a considerable fraction of patients are considered
over-treated [11].
Several gene expression profiling strategies were used to stratify breast cancer.
Analysis of gene expression identified five intrinsic molecular subtypes asso-
ciated with survival in breast cancer: luminal A, luminal B, basal, HER2-like
and normal-like subtypes [117, 118]. The majority of luminal breast cancers are
positive for estrogen receptor, and luminal B tumors have worse prognosis than
luminal A [119]. Basal breast cancers are mainly triple-negative (ER-, PR-, HER2-)
with bad prognosis [119, 120]. The intrinsic subtypes were also used to build
a supervised risk predictor of breast cancer recurrence [121]. Two other gene
expression signatures were developed to predict the risk of distant metastasis and
were translated into diagnostic tests [122, 123].
Only three driver genes in breast cancer are mutated in more than 10% of patients:
PIK3CA, TP53 and GATA3 [120]. However, a long tail of low-frequency drivers
illustrate the high level of heterogeneity in breast cancer [57]. Breast cancer is
in fact considered to belong to a class of cancers dominated by copy number
alterations [124]. Several oncogenes are amplified in more than 20% of breast
cancers including MYC, ERBB2 (also known as HER2), ZNF703 and CCND1 [125].
Integrative clustering of both gene expression and copy number alterations identified
10 groups of patients with distinct survival association [125]. Predictive scores for
chemotherapy sensitivity were developed using patterns of loss of heterozygosity
and allelic imbalance in triple-negative breast cancers [126].
Breast cancers have variable extents of intra-tumor heterogeneity and subclonal
driver mutations within the primary tumor [127]. Distant metastasis, as well as
locoregional relapse, were found to be seeded by subclones in the primary tumor
[127, 128]. However, distant metastases had a wider repertoire of driver genes
than locoregional relapses and primary tumors [128, 129]. Treatment can have a
dramatic influence on the clonal architecture of breast cancer, which can lead to drug
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resistance [130]. In particular, acquired mutations in estrogen receptor α encoded
by the ESR1 gene were found to drive resistance to hormonal therapy antagonizing
estrogen receptor in ER+ cancers [131]. On the other hand, chemoresistance
in triple-negative breast cancers was shown to occur via adaptive selection of
pre-existing genotypes and acquired reprogramming of transcriptional profiles
[132].
2.5 Analysis of cancer genome data
2.5.1 High-throughput sequencing technologies
High-throughput sequencing (HTS), also known as next generation sequencing, is
a sequencing technology that allows the examination of billions of DNA templates
in a single instrument run [133]. Several HTS instruments are available from
different manufacturers such as Illumina, Oxford Nanopore, Pacific Biosciences
and ThermoFisher Ion Torrent. These instruments vary in the technologies used,
the number of reads produced each run and the length of sequencing reads [133].
Illumina instruments, used in the studies of this thesis, allow sequencing a very high
number of reads per run but at a short read length. To compensate for the short length
of the reads, Illumina sequencers support paired-end sequencing, in which both
ends of the same DNA fragment is sequenced to the same read length. Paired-end
sequencing enhances the alignment to the reference genome and also allows a better
detection of structural variations [42]. Therefore, Illumina sequencing has been
the most popular choice for resequencing experiments such as exome sequencing,
whole-genome sequencing (WGS) and other read counting applications such as
RNA sequencing (RNA-Seq) and chromatin immunoprecipitation sequencing.
Exome sequencing targets the exons of protein coding genes providing higher
sequencing coverage (the average genome-wide or exome-wide sequencing depth)
at a reduced cost in comparison to WGS [134].
2.5.2 Alignment to the reference genome
Alignment involves finding the chromosomal locations from which the reads have
most likely originated. Considering the massive number of reads produced by
HTS experiments, the large size of the human genome, and the large genomic
regions with repetitive sequences, alignment is the most computationally intensive
task when analyzing cancer genomes. Alignment algorithms need not only to be
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computationally effective in mapping sequencing reads, but also accurate in doing
so. The accuracy of the alignment has a crucial effect on the quality of detecting
point mutations and structural variations from aligned sequencing data [42, 135].
The most commonly used aligners are the Burrows Wheeler Aligner (BWA) and
Bowtie2 [136, 137]. Both BWA and Bowtie2 support fast gapped alignment with
mismatches to account for possible variations in the genome. Other preprocessing
steps typically follows alignment such as sorting reads by coordinate, and marking
or removing duplicates (reads that have likely originated from the same original
DNA fragments).
2.5.3 Detection of somatic mutations
Accurate detection of somatic mutations is crucial in the era of precision medicine.
The statistical methods used for detection of somatic mutations, also called somatic
variant callers, typically requires matched tumor-normal sample pairs that have
been aligned to a reference genome. The matched normal sample, which can
be derived from blood or adjacent normal tissue, is used to eliminate inherited
germline variations. Somatic variant callers scan the entire genome, or exome,
for mismatching basepairs or small insertions and deletions. Read count statistics
in both the normal and tumor samples are collected together with various other
informative metrics for each recorded mismatch. Finally, each recorded mismatch is
either accepted as a somatic mutation or rejected as an artifact or germline variation
based on a specified statistical model. The candidate variants could also undergo a
set of hard filters defined by the user. This general workflow is followed by several
variant callers such as MuTect, Varscan and Strelka [138, 139, 140].
Several biological and technical factors challenge the seemingly simple workflow
of variant callers, leading to relatively low concordance between different analysis
pipelines [135]. Intra-tumor heterogeneity (ITH), aneuploidy and tumor purity
deviate the expected variant allele frequencies between different samples [141].
ITH and aneuploidy can also lead to deviations in variant allele frequencies between
different regions in the genome of the same sample. Mutations with exceedingly
low variant allele frequencies ultimately become indistinguishable from technical
artifacts. Artifacts can arise as a result of sequencing errors, alignment errors or
DNA damage during tissue fixation (formalin-fixed paraffin-embedded [FFPE]
induced artifacts) or during library preparation (8-oxoguanine artifacts) [142, 143].
The accuracy of variant callers is largely dependent on local sequencing depth,
which is the number of reads mapping to the local genomic region. Higher
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sequencing depth increases the power for detection of somatic mutations especially
in cancer samples with low purity [144].
2.5.4 Detection of somatic copy number alterations
Somatic copy number alterations (SCNA) affect a large fraction of the genome dis-
rupting up to thousands of genes [145, 146]. SCNAs are detected from sequencing
data using depth of coverage methods. The number of copies for a chromosomal
segment is proportional to the local sequencing depth for that segment. Therefore,
the workflow for SCNA callers starts from computing the ratio of read counts
(local depth of coverage) between the tumor and matched normal samples at
non-overlapping windows, exons, or single nucleotide polymorphisms (SNPs).
Normalization typically follows to account for inherent sequencing biases in the
depth of coverage such as GC-content, mappability, library size or hybridization
affinity (exome sequencing) biases. Next, chromosomal segments with similar
values of the log-ratios are identified using a segmentation algorithm such as the
circular binary segmentation algorithm [147]. Chromosomal segments with high
and low log-ratios are then called amplifications and deletions, respectively.
Detection of copy-neutral loss of heterozygosity (cnLOH) requires the quantifica-
tion of B-allele frequencies (BAFs). BAF represents the fraction of reads exhibiting
the alternative allele in germline SNPs. The expected value for BAF is 0.5 for a
heterozygous SNP in the normal sample. This value will deviate from 0.5 in the
tumor sample at chromosomal regions with imbalanced amplification or deletion of
a single allele. BAFs can be incorporated in the segmentation step or overlaid on an
existing segmentation. Segments with neutral log-ratios but deviated average BAF
values are called cnLOH.
To convert the log-ratios to the corresponding absolute number of copies, estimation
of ploidy and purity of the sample is needed. Ploidy and purity can be estimated
jointly from the segmented copy number profile, such that the converted absolute
copy number for all chromosomal segments in the genome is the closest possible
to integer values [148, 144]. Estimating the purity-adjusted absolute copy number
profile is advantageous for interpretation and analysis of cancer genomes. First,
defining thresholds for amplifications and deletions using purity-adjusted copy
number leads to better sensitivity in samples with low tumor content. Second,
detection of genome doubling events, which are common in cancer and associate
with poor prognosis [41], becomes possible. Finally, the multiplicity (or cancer cell
fraction) of somatic mutations can be computed from variant allele frequencies when
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purity and absolute copy number values are known [144]. Mutation multiplicities
are especially useful in deciphering the evolutionary history and clonal ordering of
cancer subpopulations [149].
2.5.5 Detection and quantification of mutational signatures
The catalog of somatic mutations in cancer genomes carries imprints of mutational
processes that have been active throughout the cellular lineage of cancer cells
[150]. It has been known even before the era of high-throughput sequencing that
mutagens such as UV light and tobacco smoking induce unique spectra of mutations
[151, 152]. With high throughput sequencing, examination of the full catalog of
somatic mutations in cancer genomes became possible. Each mutational catalog
is a representative record of a mixture of unique signatures of different mutational
processes. The computational challenge is to isolate the spectra of the mutational
signatures and quantify their exposures in crafting the observed mutational catalog.
This resembles a blind source separation problem that involves the isolation and
quantification of hidden signals from a set of mixtures of these signals [153].
Non-negative matrix factorization (NMF) is an algorithm for learning part-based
representation of objects such as images or text [154]. NMF is the first and most
commonly used algorithm for deciphering the signatures of mutational processes
in cancer genomes [155, 49]. NMF corresponds to factorizing a matrix A into two
non-negative matrices: A ~WH. The most commonly used approximation employs
simple multiplicative updates [156, 157].
The spectrum of point mutations is often represented by the type of substitution
(C:G>A:T, C:G>G:C, C:G>T:A, T:A>A:T, T:A>C:G, T:A>G:C) and the trin-
ucleotide sequence context of each mutated base leading to 96 possible classes
(6 substitution types × 16 possible trinucleotide contexts). A matrix of counts
for each class of mutation in each cancer genome (or exome) is used as an input
to the NMF algorithm. NMF decomposes the input matrix into two matrices
under the non-negativity constraint. The first output matrix includes the mutational
spectra for N signatures, and the second output matrix contains the exposure
of each of the N signatures in each cancer genome (or exome). The number
of signatures N is pre-specified to the NMF algorithm. A suitable number of
signatures can be found by running the NMF analysis on multiple values for N
and choosing the value that minimizes the reconstruction error and maximizes the
cophenetic correlation (similarity between extracted signatures at different random
runs) [155]. Several factors limit the accurate extraction of mutational signatures
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such as low number of mutations per sample, low number of samples and the high
similarity between signatures [155]. To overcome the number of samples limitation,
alternative approaches have been developed to estimate the exposure of reliably
known signatures in each single sample [158].
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3 Aims of the study
1. To enhance the molecular stratification of diffuse large B-cell lymphoma
thereby guiding clinical decision making. (Publication I)
2. To characterize and understand the metastatic spreading patterns in breast
cancer. (Publication II)
3. To benchmark and compare the performance of somatic copy number alter-
ation detection methods from whole-genome and exome sequencing data.
(Publication III)
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4 Materials and methods
4.1 Biological sample material
Table 1 lists the cancer sample datasets used in each publication, the measurement
technologies and sources of the data.
Publication Samples Technology Source
Publication I
Matched primary-relapse
sample pairs from seven
patients
WGS, RNA-Seq In house
Primary DLBCL samples
from 97 patients
WGS (39 samples),
RNA-Seq (97 samples)
Cancer Genome
Characterization
Initiative (CGCI)
(phs000532) [159]
Primary DLBCL samples
from 414 patients
Affymetrix gene
expression microarrays
Gene Expression
Omnibus (GEO)
(GSE10846) [99]
Primary DLBCL samples
from 470 patients
Affymetrix gene
expression microarrays
GEO
(GSE31312) [160]
Primary DLBCL samples
from 521 patients
RNA-Seq (234 samples)
and exome sequencing
(521 samples)
Genomic Data
Common [106]
Primary DLBCL samples
from 101 patients
Affymetrix gene
expression microarrays
GEO
(GSE98588) [107]
Primary DLBCL samples
from 383 patients
RNA-seq (383 samples)
and WGS (153 samples)
Study in
reference [161]
Primary DLBCL samples
from 604 patients
RNA-seq and
exome sequencing
Study in
reference [104]
Publication II
99 samples from 20
breast cancer patients.
The samples included
primary tumors, axillary
lymph node metastasis and
distant metastasis samples.
Exome sequencing In house
Publication III
Primary breast cancer
samples from 4 patients
WGS, Exome
sequencing and
SNP arrays
The Cancer
Genome Atlas
(TCGA) [120]
Table 1: Cancer sample materials used in Publications I-III
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4.2 Processing of sequencing data (I – II)
Raw paired-end sequencing reads for WGS of DLBCL samples (Publication I)
and exome sequencing of breast cancer samples (Publication II) were mapped
to the human reference genome hg19 using BWA [136]. Following alignment,
several preprocessing steps were performed including sorting by coordinates and
marking duplicates using PICARD tools [162], base quality score recalibration and
realignment around indels using the Genome Analysis ToolKit (GATK) [163]. Raw
paired-end RNA-Seq reads in Publication I were processed using the Sepia pipeline
[164] as the following. Trimmomatic [165] was used to trim Illumina adapter, when
present, and low quality bases at either end, keeping only reads with at least 25 bp
of length after trimming. Alignment to human reference genome was done using
STAR 2-pass mapping with regenerated genome [166]. Expression quantification
was done using eXpress [167]. All the processing workflows were built with the
Anduril framework for scientific data analysis [168, 169].
MuTect/MuTect2 [138] was used to identify variants from WGS data (Publication
I) and exome data (Publication II). In cases where multiple cancer samples per
patient were sequenced, a forced calling approach was used. In forced calling, each
detected variant in at least one sample undergoes counting reads supporting the
reference and the detected variant allele in all other samples from the same patient.
Specialized variant filtering criteria were applied on called variants to account for
possible sources of artifacts in each study design. For example, to account for
FFPE artifacts that manifest as low frequency C>T substitutions, sample-specific
C>T substitutions were required to have a variant allele frequency of at least 0.15
in Publication II. The final variants were then annotated for functional prediction
using Annovar [170]. SCNAs were detected using Ascat following the AscatNGS
workflow [148, 171].
4.3 Mutational signatures analysis (I – II)
In Publication I, a clustered mutation signature approach was used in order to
allow the isolation of mutational processes with localized mutagenesis [172]. Each
mutation was annotated with the distance to the adjacent mutation that has the same
substitution and strand orientation. Based on the distance, point mutations were
classified into clustered (distance < 1000 basepairs) or unclustered (distance ≥
1000 basepairs). Incorporating the clustering classification expanded the classes of
substitutions from 96 to 192. Clustered mutation signatures were then extracted
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using the NMF algorithm. In Publication II, NMF was used to extract mutational
signatures using the standard 96 classes of substitutions. NMF was executed using
the NMF and SomaticSignatures R packages [173, 174]. The number of signatures
was decided by running NMF with several values of N (number of signatures) and
choosing a suitable N based on cophenetic correlation and reconstruction error.
4.4 Phylogenetic analysis (II)
Somatic single nucleotide substitutions were used to construct phylogenetic trees
using the Dollo parsimony [175], which has the main assumption that the same
mutation can only be gained once in an evolutionary trajectory. The confidence
of each constructed tree was estimated using 1000 boostraps. The constructed
trees were further validated using an orthogonal method called LICHeE [176].
LICHeE uses variant allele frequencies (VAFs) to build the trees under the following
constraints. First, a mutation shared by a group of samples cannot be a successor
to a mutation shared by a smaller subset of the same group. Second, the VAF of
a given mutation cannot be higher than the VAF of its predecessor. Last, the sum
of VAF values of mutations disjointly present in distinct subclones cannot exceed
the VAF value of a common predecessor mutation [176]. The linear and parallel
progression modes were inferred from the topography of the trees.
4.5 Identification of SHM subtypes in DLBCL (I)
The first step was to identify the genes targeted by somatic hypermutation (SHM).
Motivated by the detected clustered mutation signatures, two mutational patterns
(mutations in RCH or TW context) associated with SHM were used separately in the
analysis. We restricted the analysis to genomic regions up to 2500bp downstream of
transcription start sites of protein coding genes. Our choice was based on previous
literature on SHM targeting [82, 90, 89] and based on our exploratory analysis.
A one-sided binomial test was used to identify genes whose target regions had
an unexpectedly high number of RCH or TW mutations in comparison to the
background mutation rate. Genes with p-values < 0.1 after adjustment for multiple
hypotheses testing using the false discovery rate (FDR) method by Benjamini &
Hochberg [177] were considered significant. In the second step, gene expression
of the identified target genes in 97 primary DLBCL samples were clustered using
consensus hierarchical clustering as implemented in the ConsensusClusterPlus
R package [178, 179]. Cluster centroids were computed as the average Z-score
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normalized gene expression of samples belonging to each cluster. Classification of
new samples in validation sets was done by assigning each sample to the cluster of
the nearest centroid.
4.6 Benchmarking SCNA detection algorithms (III)
Comparison of 10 methods for SCNA detection was performed using simulated
sequencing data and cancer samples from TCGA. The compared SCNA detection
methods included BICseq [180], HMMcopy [181], CNAnorm [182], SegSeq [183],
COPS [184] and CNAseg [185] for WGS data, ExomeCNV [186], VarScan2 [139]
and ADTEx [187] for exome data, and ControlFreeC [188, 189] for both WGS
and exome data. Simulated sequencing data used chromosome 22 as a template to
which SCNAs with different types and sizes were introduced by RSVSim [190].
To create simulated sequencing reads from the altered chromosome 22, wgsim
from the samtools package was used [191]. Simulated reads were mapped to the
reference genome by BWA and Bowtie2 [136, 137]. SCNA calls from the different
algorithms were compared with the ground truth created by RSVSim for evaluation.
To evaluate the methods in cancer sequencing data, the concordance between SCNA
calls for each algorithm and SNP array results was evaluated.
4.7 Statistical analysis (I – III)
Statistical analysis in all the three publications was done in R. Statistical tests
were two-sided unless otherwise specified. Correction for multiple hypotheses
testing was performed whenever needed. In Publication I, survival analysis was
done using the survival R package and visualized using the survminer R package.
Overall survival was defined from the date of diagnosis to last followup or death
from any cause. In Publication III, sensitivity and specificity were used to evaluate
SCNA methods in simulated data. Sensitivity was computed as as the proportion
of the ground truth regions called correctly by an SCNA method. Specificity was
calculated as the compliment to false positive rate, and was computed as the length
of non-overlapping genomic regions between the ground truth and called SCNAs
divided by the length of genomic regions not in the ground truth. The Jaccard index
was used to measure the concordance with SNP arrays in cancer data.
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5 Results
5.1 Exposure to SHM mutational processes delineate the cell of
origin in DLBCL (I)
Using WGS data from 53 samples, we extracted four signatures of mutational
processes in DLBCL. Two signatures were similar to the previously identified
Signature 5 and Signature 17 (both with unknown etiology) [49]. The third signature
(labeled Signature TW) was characterized by clustered mutations at TW context (T
is A or T) attributed to error-prone repair by polymerase η . The fourth signature
(labeled Signature RCH) was characterized by clustered mutations at RCH context
(R is A or G; H is C, T or A) attributed to AID mediated mutagenesis [192].
Mutations at RCH and TW contexts are characteristic of somatic hypermutation
(SHM) [86].
Examination of the exposure of mutational processes in DLBCL indicated a striking
difference between the ABC and GCB subtypes. Contribution of Signature TW
was significantly higher in the GCB subtype, whereas the contribution of Signature
RCH was significantly higher in the ABC subtype. The high contrast in the activity
of SHM-related mutational processes between the ABC and GCB subtypes was
sufficient to correctly classify 30 out of 35 DLBCL samples (86%) with either of
the two subtypes. The results were validated in an extended set of 153 DLBCL
samples with WGS, where the exposure of SHM mutational processes determined
the ABC/GCB subtype correctly in 71 out of 91 DLBCL samples (78%).
5.2 Distinct transcriptional subtypes of DLBCL defined by hyper-
mutated genes (I)
We examined the rate of clustered TW and RCH mutations within a region of
2500 basepairs downstream of transcription start site of each gene, and identified
38 target genes of RCH mutations and 16 target genes of TW mutations. Since
SHM mutational processes are distinctive of the cell of origin in DLBCL and given
the transcriptional dependence of SHM, we hypothesized that the expression of
SHM target genes may identify biologically meaningful patterns in DLBCL. To
verify our hypothesis, we conducted consensus hierarchical clustering of 36 SHM
target genes in 97 DLBCL samples with RNA sequencing data. Four clusters
(denoted SHM subtypes [SHM1-4]) with distinct association to COO subtypes
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Figure 7: Schematic of the study in Publication I. Clustering of 36 SHM target genes
identified four SHM subtypes used for classification of DLBCL samples. The figure is
modified from Alkodsi et al., unpublished.
were identified. SHM1 and SHM3 were predominated with GCB cases, whereas
SHM2 and SHM4 had a majority of ABC cases. Overall survival was different
between the SHM subtypes, and especially between each two groups of the same
COO subtype majority. In particular, among GCB enriched subtypes, SHM1 had
a worse prognosis than SHM3, and among ABC enriched subtypes, SHM2 had a
worse prognosis than SHM4. A schematic illustration of the discovery of the SHM
subtypes is shown in Figure 7.
The SHM subtype assignment was performed by nearest centroid classification in
the Lenz et al. CHOP and R-CHOP treated cohorts [99], Visco et al. [160], Schmitz
et al. [106], Chapuy et al. [107], Reddy et al. [104], and Arthur et al. [161] cohorts.
The proportions of ABC and GCB cases in each SHM subtype were similar in
all tested cohorts. The SHM subtypes were significantly associated with overall
survival in Lenz et al. cohorts (CHOP cohort: p = 0.0006; R-CHOP cohort: p <
0.0001), Visco et al. (p = 0.0005), Schmitz et al. (p < 0.0001), Reddy et al. (p
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= 0.001), and Arthur et al. (p = 0.0059) cohorts. Progression-free survival was
significantly different between the SHM subtypes in Visco et al. (p < 0.0001) and
Schmitz et al. (p < 0.0001) cohorts. Time-to-progression differed significantly
between the SHM subtypes in the Arthur et al. cohort (p = 0.0018).
Meta-analysis of DLBCL patients treated with immunochemotherapy (R-CHOP
like treatment) indicated a significant association of the SHM subtypes with overall
survival (1,642 patients from five cohorts; p< 0.0001) and progression-free survival
(795 patients from three cohorts; p < 0.0001). The SHM subtypes remained
significant in multivariate analyses of overall and progression-free survival using
Cox proportional hazard regression model that included the IPI score and COO
subtypes. In a COO subtype specific analysis, the SHM subtypes had a significantly
different overall and progression free survival within the ABC and GCB subtypes.
Surprisingly, overall survival was significantly different between the SHM subtypes
in the obscure minor unclassified subtype of DLBCL. These results indicate that
the SHM subtypes confer an additional prognostic value beyond the IPI scores and
COO subtypes.
5.3 The SHM subtypes of DLBCL are associated with distinct
genetic alterations (I)
To characterize the genomic landscape of the SHM subtypes, we used the genomic
alterations data from Schmitz et al. (521 samples) and Reddy et al. (604 samples)
cohorts. The alterations attributed to each of the SHM subtypes were highly
similar between the two cohorts, indicating the robustness of the SHM subtype
classification.
SHM1 (GCB majority with bad prognosis) was characterized by increased fre-
quency of BCL2 and MYC translocations that were not necessarily concurrent,
alterations in the chromatin remodeling and histone modification pathways such
as mutations in KMT2D and EZH2, alterations targeting the G-protein signaling
pathway such as mutations in GNA13 and GNAI2, and chromosomal duplication
of chromosomes 7 and 12. SHM2 (ABC majority with bad prognosis) had a
high frequency of MYD88 (L265P) and CD79B mutations in addition to other
alterations that characterize the ABC subtype such as PIM1, ETV6, IRF4 mutations
and CDKN2A deletions. Chromosomal duplication of chromosomes 3 and 18 were
particularly common in SHM2. SHM3 (GCB majority with good prognosis) had a
high frequency of alterations in the JAK-STAT pathway such as SOCS1, STAT3 and
STAT6 mutations in addition to mutations in SGK1, IRF8 and TNFAIP3. Finally,
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SHM4 had the highest frequency of BCL6 fusions as well as CD70, BCL10 and
SPEN mutations. Collectively, each of the SHM subtypes had a distinct genetic
profile that could potentially be targeted by novel therapies in DLBCL.
5.4 Linear and parallel spreading of breast cancer distant metastasis
(II)
Among 20 studied breast cancer patients, five patients with exome sequencing of
primary tumor and multiple distant metastasis sites were used to study the spreading
of distant metastasis in breast cancer (patients 1, 4, 5, 8 and 19). Phylogenetic
analysis of mutation data indicated that tumors from four patients (1, 5, 8 and
19) followed a linear progression model of successive metastasis-to-metastasis
spreading [39]. In all the four cases, distant metastases from different anatomical
sites (liver and lung metastases from patient 1, two bone relapses from patient 5, skin
and bone metastases from patient 8, and two brain relapses from patient 19) were
genetically more similar to each others than to their primary tumor. Interestingly, the
seeding clone shared among different metastases harbored putative driver alterations
that were not detected in the primary tumor.
In contrast, tumor in patient 4, from whom six regions from the primary tumor
and three distant metastasis sites were exome sequenced, followed the parallel
progression model [39]. Phylogenetic analysis indicated that the three distant
metastasis sites (brain, colon and uterus) were seeded directly by the primary tumor
(likely from different subclones in the primary tumor) and evolved independently
in parallel further acquiring new unique genetic alterations. These results show
that both of the debated progression models of metastasis dissemination (linear
and parallel) occur in breast cancer, but in different cases. The prevalence of each
model, however, remains unclear.
5.5 No involvement of synchronous axillary lymph node metastasis
in distant metastasis seeding (II)
We investigated the role of axillary lymph node (ALN) metastasis in seeding
distant metastasis in eight breast cancer patients from whom primary tumor, ALN
metastasis and distant metastasis were exome sequenced (patients 2, 3, 8, 10,
14, 15, 17, and 18). The phylogenetic analysis of point mutations from these
patients indicated that distant metastasis seeding from ALN metastasis was unlikely
(maximum probability 0.23 in patient 8 while all other patients had a near zero
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probability). In three of these patients (patients 2, 10, and 1), the sequenced ALN
represented the only positive ALN from these patients, excluding the possibility of
distant metastasis seeded by unsequenced ALN. However, the possibility of distant
metastasis seeded by an unsequenced region of the ALN cannot be excluded despite
being unlikely to repeatedly be the case in all the eight patients.
5.6 Activity of mutational processes during breast cancer progression
(II)
We extracted four signatures of mutational processes (labeled S1-4) that have been
operational in the breast cancer cohort. Three of the four extracted signatures were
mapped to previously identified signatures with known etiologies (S1, S2 and S4).
Signature S1 was characterized mainly by C>T transitions in CpG context resulting
from spontaneous deamination of 5-methyl-cytosines, and was associated with
age at diagnosis [49]. Signature S2 had an excess of C>T and C>G mutations in
the TpCpN context attributed to the activity of the APOBEC family of cytidine
deaminases [193]. Signature S4 was mapped to the known Signature 3 that has
been attributed to deficient homologous recombination (HR) in double-strand break
repair.
We evaluated the exposure of the mutational processes in different categories
including truncal, primary-specific, ALN-specific, local recurrence specific and
distant metastasis-specific mutations. All the four signatures had a significantly
different contribution between the different categories of mutations (p < 0.01;
Kruskal-Wallis test). The contributions of signatures S1 (APOBEC), S3 (Unknown
etiology) and S4 (HR deficiency) were significantly higher in mutations specific to
distant metastasis in comparison to the ones specific to primary tumors (p < 0.05;
Mann-Whitney U test with FDR correction). On individual level, 15 patients had
an increased activity of one of the three (S1, S3 and S4) signatures in metastasis
in comparison with the corresponding primary tumor (p < 0.05; Fisher’s exact
test with FDR correction). In patient 4, the significant increase in Signature S4
contribution accompanied two BRCA2 mutation gained in two different distant
metastasis sites. The increase of exposure of a specific mutational process did not
associate with the molecular subtype of breast cancer or the treatment of the patient.
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5.7 Assessment of SCNA detection algorithms from deep sequencing
data (III)
The performance of ten SCNA detection algorithms was performed using simulated
sequencing data as well as real breast cancer sequencing data. Various aspects of
the algorithms’ performance were evaluated using four simulation groups. Each
group consisted of 10 simulated WGS and exome samples having a known set of
SCNAs with specific characteristics.
The sensitivity of SCNA detection algorithms in WGS data (BICseq, HMMcopy,
CNAnorm, SegSeq, COPS and ControlFreeC) was evaluated using the simulation
group 1 that included various SCNAs of different classes of size (< 1 Kbp, 1 –
10 Kbp, 10 – 100 Kbp, 100 kbp – 1 Mbp and >1 Mbp) and type (homozygous
deletions, heterozygous deletions, gains of one copy, gains of two copies and
high-level amplifications). SCNAs with small size were more challenging to detect
as exemplified by the lower sensitivity of their detection by all algorithms. BICseq,
SegSeq and COPS were specifically better at detecting smaller SCNAs than the
other algorithms. The types of SCNAs did not have a large influence on the detection
power, except for gains of one copy, which were more difficult to detect than other
types.
The sensitivity of SCNA breakpoint localization was assessed also using the
simulation group 1. The accuracy was determined as the distance in basepairs
between the actual (ground truth) and the detected breakpoints. The breakpoints
were considered in sensitivity assessment only when the overlap between the
detected SCNA and the ground truth exceeded 70% of the size of both detected
and ground truth SCNA. BICseq and SegSeq had the best accuracy for breakpoint
localization, owing to their unique approaches that differ from the window approach
utilized by the other algorithms. The performance of SCNA detection algorithm
from exome data was similar between the algorithms (Control-FreeC, ExomeCNV,
ADTEx and Varscan), since it depends on the inter-exonic distance rather than the
methodology of the algorithms. As expected, the accuracy of WGS algorithms in
breakpoint localization was significantly higher than exome algorithms.
The effect of complex copy number events (adjacent SCNAs sharing common
breakpoints) on the performance of the algorithms was assessed in three simulation
groups. Samples in simulation group 3 had the possibility of having adjacent
SCNAs, in contrast to simulation group 2, in which adjacent SCNAs were not
allowed. Samples in simulation group 4 had complex SCNA events spanning the
whole chromosome. The presence of complex events did not significantly affect
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the performance of the algorithms as exemplified by the similar sensitivity and
specificity of the different algorithms between simulation groups 2 and 3. However,
the performance heavily deteriorated in simulation group 4 when the complex
events spanned the whole chromosome. The observed drop in performance was
due to the inconsistency of estimating the baseline ploidy between the different
algorithms.
To evaluate the SCNA detection algorithms in real sequencing data, we used four
breast cancer samples from TCGA characterized by WGS, exome sequencing
and SNP arrays. We used SCNAs called from SNP arrays as a reference for
evaluation. The Jaccard index was used to measure the concordance between
SCNAs detected by the different algorithms in WGS or exome sequencing and those
found by SNP arrays. The average concordance in WGS algorithms ranged between
0.645 (HMMcopy) and 0.451 (CNAnorm). In exome sequencing algorithms, the
concordance with SNP arrays was significantly lower, ranging between 0.405
(ExomeCNV) and 0.235 (ADTEx).
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6 Discussion
The three studies presented in this thesis provided various kinds of clinical, bio-
logical and technical insights in the field of cancer genomics. In Publication I, the
proposed classification system informs on the pathogenesis and the biology of four
unique disease entities in DLBCL, and may potentially have clinical applications.
Publication II sheds light on the evolutionary origin of metastasis in breast cancer,
and provides answers on previously debated progression models of the disease.
Publication III gives a technical overview of the computational methods used for
detection of somatic copy number alterations from cancer genomes. The findings
of the three studies and their implications exemplify the wide range of insights that
can be obtained by the computational analysis of cancer genomes.
The major implication of the first study is the ability to stratify DLBCL patients into
biologically distinct groups that may differentially benefit from altered treatment
options. Both SHM1 and SHM3 have a majority of cases with GCB cell of origin,
but they significantly differ in their clinical outcome after R-CHOP standard therapy.
The SHM1 group, which has a dismal outcome, may benefit from a modified
treatment strategy unlike the SHM3 group, which has excellent outcome with
standard treatment. The genetic landscape of the SHM1 group was characterized by
alterations in BCL2 and MYC that were not necessarily concurrent, in addition to
mutations in histone-modifying genes such as EZH2 and KMT2D. These alterations
pinpoint the specific vulnerabilities in this subtype that can be targeted by novel
treatments. The SHM2 and SHM4 subtypes include mainly ABC DLBCLs, but
also significantly differ in their survival after R-CHOP treatment. SHM2 has the
most dismal outcome among the four SHM subtypes, and therefore, has the highest
priority for adjustment in the treatment. Targeting the B-cell receptor in the SHM2
subtype may be beneficial given the enrichment of genetic alteration in the B-cell
receptor signaling pathway [194].
Publication I also sheds light on the mutational processes that have been active
throughout the lifetime of lymphoma progenitor cells. Two mutational processes
related to somatic hypermutation were particularly interesting, as their activity
segregated with the cell of origin of DLBCL. A process attributed to error-prone
repair by polymerase η was highly active in the GCB subtype, unlike the second
process characterized by mutations attributed to AID mutagenesis, which was highly
active in the ABC subtype. This highlights the distinct repair pathways utilized by
each subtype upon cytosine deamination by AID, and motivates further functional
studies on DNA repair in DLBCL. Additionally, the high contrast between the ABC
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and GCB subtypes suggests that the activity of mutational processes could be an
important component in a classifier that determines the cell of origin in DLBCL
using non-invasive genetic testing.
The major finding in Publication II was the lack of lymphatic seeding of distant
metastasis in breast cancer, and thereby providing the first genetically-derived
evidence of the redundancy of lymph node dissection in breast cancer. Lymph
node involvement is undoubtedly an important prognostic factor that predicts
worse outcome and an aggressive phenotype in breast cancer [195]. However,
our results in Publication II support the notion that lymph node involvement
may reflect the metastatic capability of the tumor, rather than mechanistically
contributing to metastasis. Indeed several clinical trials have shown that lymph
node dissection had little to no effect on patient survival [196, 197, 198], which
further support our findings. A similar study investigating the lymphatic seeding
of distant metastasis in colorectal cancer concluded that lymphatic and distant
metastases arose independently from primary tumor in 65% of the cases, while
in the rest, an evidence of lymphatic seeding was found [199]. Therefore, the
prevalence of lymphatic seeding may vary between different types of cancers, and
further studies in other cancers are needed to understand the factors that affect
lymphatic seeding.
The results of Publication II showed that the spreading patterns of breast cancer vary
in different cases. Linear progression or the successive spreading from a distant
metastasis site to another was detected in several cases, and was often accompanied
with acquisition of new putative driver mutations. Parallel progression from primary
tumor to multiple distant sites was also found in one of the studied cases. The
factors that influence the type of progression remain unclear. In both scenarios, the
heterogeneous nature of distant metastases complicates and limits clinical genetic
testing, as each biopsy could be distinct in the genetic makeup and targetable
mutations. Liquid biopsies and the genetic screening of circulating tumor DNA
provide a promising avenue for tackling the heterogeneity and predicting recurrence
in breast cancer [200], as well as in other cancers [201].
The change in the landscape of active mutational processes in breast cancer metasta-
sis was apparent in the majority of studied cases. A landscape characterized by aging
signature in the primary tumor fades in metastasis giving rise to other mutational
processes. The exposure to a mutational process attributed to activity of APOBEC
family of cytidine deaminases showed a significant increase in distant metastasis.
The increased activity of APOBEC-mediated mutagenesis upon recurrence was
observed in several cancers [25], and linked to the acquisition of subclonal driver
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mutations [202]. Two treatment strategies were suggested to tackle APOBEC
mutagenesis. The first is by increasing mutation rate to an unsustainable level
of DNA damage that eventually leads to cell death [203], and the second is by
decreasing mutation rate via the inhibition of APOBEC gene expression [204].
Both Publication I and Publication II highlighted the important role of hypermuta-
tion either in the form of AID mutagenesis in DLBCL or APOBEC mutagenesis
in breast cancer. Both AID and APOBEC belong to the same family of cytidine
deaminases inducing localized mutations in the genome. Localized mutations in
breast cancer, known as kataegis, were linked to a gene expression signature that
was associated with prognosis and Her2 status [205]. The patterns of clustered
mutations were found to be widespread in cancer [172]. Investigation of the
genetic-transcriptomic interplay of these mutational processes may lead to important
discoveries in several types of cancer.
Publication III highlights the technical difficulties resulting from analyzing cancer
genome data from different platforms. The computational methods that operate
on whole-genome sequencing showed a superior performance in comparison to
exome sequencing. Another remarkable obstacle was the difficulty of estimating
the baseline level for copy number estimation in the cases where a large proportion
of the genome is altered. However, since the time of publication, several recent
methods for analyzing SCNAs from cancer genomes and exomes have tackled these
difficulties. Several recent methods operating on exome sequencing successfully
utilized panels of normal controls and/or the off-target aligned sequencing reads to
eliminate hybridization bias often seen in exome sequencing [206, 207]. Estimation
of ploidy and purity is currently a main analysis performed by several SCNA
methods utilizing allele-specific information inherent in heterozygous SNPs [208,
209, 210]. Indeed, a choice of a method that is able to estimate ploidy and
purity was necessary in Publication II. Benchmarking the performance of different
bioinformatics tools is therefore a crucial task towards applied clinical genomics.
The last decade has witnessed an explosive growth of data collection in several
fields and industries. Artificial intelligence and machine learning algorithms have
already become a backbone in many data-driven industries. As biological and
sequencing data accumulate, the performance of machine learning algorithms will
surge, and more applications of artificial intelligence in health care, medicine and
genomics will emerge [211]. The increasingly important role of bioinformatics and
computational biology will continue the rise in a next era of cancer genomics.
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